The National Institute for Health and Care Excellence (NICE) has recommended FILSPARI (sparsentan) for use in the NHS in England as a treatment for primary IgA nephropathy. The decision follows UK regulatory approval and is based on results from the phase 3 PROTECT trial.
NICE’s guidance states that sparsentan can be prescribed to adults with a urine protein excretion of 1.0 g/day or more, or a urine protein-to-creatinine ratio of 0.75 g/g or more. To ensure treatment efficacy, NICE has advised that only patients showing response should continue the therapy…